Precigen Investor Credits Papzimeos Launch for Strong Gains
Patient Opportunity Equity Strategy credited the drug’s launch with driving gains and pointed to cancer trials and other pipeline programs.
Makkler Newsroom · Oct 12, 06:52 PM · 1 min read
Market open· · USD · Data may be delayed
Avg. target $13.67 (+212.4%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO